ATE485836T1 - Mrt-geführte photodynamische therapie gegen krebs - Google Patents

Mrt-geführte photodynamische therapie gegen krebs

Info

Publication number
ATE485836T1
ATE485836T1 AT05853048T AT05853048T ATE485836T1 AT E485836 T1 ATE485836 T1 AT E485836T1 AT 05853048 T AT05853048 T AT 05853048T AT 05853048 T AT05853048 T AT 05853048T AT E485836 T1 ATE485836 T1 AT E485836T1
Authority
AT
Austria
Prior art keywords
mri
photodynamic therapy
cancer
treatment
disclosed
Prior art date
Application number
AT05853048T
Other languages
English (en)
Inventor
Zheng-Rong Lu
Anagha Viadya
Tianyi Ke
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Application granted granted Critical
Publication of ATE485836T1 publication Critical patent/ATE485836T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Laser Surgery Devices (AREA)
AT05853048T 2004-12-03 2005-12-02 Mrt-geführte photodynamische therapie gegen krebs ATE485836T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63325504P 2004-12-03 2004-12-03
PCT/US2005/044012 WO2006060797A2 (en) 2004-12-03 2005-12-02 Mri guided photodynamic therapy for cancer

Publications (1)

Publication Number Publication Date
ATE485836T1 true ATE485836T1 (de) 2010-11-15

Family

ID=36565853

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05853048T ATE485836T1 (de) 2004-12-03 2005-12-02 Mrt-geführte photodynamische therapie gegen krebs

Country Status (9)

Country Link
US (1) US20090076571A1 (de)
EP (1) EP1830879B1 (de)
JP (1) JP2008522666A (de)
KR (1) KR20070086803A (de)
AT (1) ATE485836T1 (de)
AU (1) AU2005311560A1 (de)
CA (1) CA2589881A1 (de)
DE (1) DE602005024437D1 (de)
WO (1) WO2006060797A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006007177D1 (de) 2005-12-05 2009-07-16 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101674852A (zh) * 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
CN101707869A (zh) * 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
WO2009055542A1 (en) * 2007-10-26 2009-04-30 University Of Utah Research Foundation Use of mri contrast agents for evaluating the treatment of tumors
EP2440247B1 (de) * 2009-06-12 2017-03-08 Erasmus University Medical Center Rotterdam Zielgerichtete nanophotomedikamente zur photodynamischen behandlung von krebs
WO2013119957A1 (en) * 2012-02-10 2013-08-15 Aidan Research And Consulting, Llc Weight reduction through inactivation of gastric orexigenic mediator producing cells
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
CN114870014B (zh) * 2022-05-18 2023-07-07 南京邮电大学 一种多功能抗肿瘤高分子药物及其制备方法和用途
WO2025160349A1 (en) * 2024-01-25 2025-07-31 Ovokaitys Todd Frank Methods and systems for improving photodynamic therapy by increasing depth of penetration without concurrently increasing energy deposition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US6534040B2 (en) * 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents

Also Published As

Publication number Publication date
JP2008522666A (ja) 2008-07-03
DE602005024437D1 (de) 2010-12-09
WO2006060797A3 (en) 2006-08-24
EP1830879B1 (de) 2010-10-27
AU2005311560A1 (en) 2006-06-08
CA2589881A1 (en) 2006-06-08
EP1830879A4 (de) 2008-09-17
EP1830879A2 (de) 2007-09-12
WO2006060797A2 (en) 2006-06-08
KR20070086803A (ko) 2007-08-27
US20090076571A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
Dupont et al. INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): study protocol for a phase I clinical trial
Bechet et al. Photodynamic therapy of malignant brain tumours: A complementary approach to conventional therapies
Beck et al. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5‐aminolevulinic acid induced protoporphyrin IX
Gheewala et al. Photosensitizers in prostate cancer therapy
Rosenthal et al. The status of contemporary image-guided modalities in oncologic surgery
Li et al. Intraoperative fluorescence-guided resection of high-grade gliomas: a comparison of the present techniques and evolution of future strategies
Meyers et al. Peptide‐targeted gold nanoparticles for photodynamic therapy of brain cancer
Wang et al. Advances in prostate‐specific membrane antigen (PSMA)‐targeted phototheranostics of prostate cancer
Bozzini et al. Photodynamic therapy in urology: what can we do now and where are we heading?
Hirschberg et al. Disruption of the blood–brain barrier following ALA‐mediated photodynamic therapy
Kochneva et al. Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials
Bugaj Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer-clinician’s insight
Jin et al. Nanoparticle‐enabled selective destruction of prostate tumor using MRI‐guided focal photothermal therapy
Shackley et al. Light penetration in bladder tissue: implications for the intravesical photodynamic therapy of bladder tumours
Arumainayagam et al. Photodynamic therapy for focal ablation of the prostate
Vaidya et al. Contrast enhanced MRI‐guided photodynamic therapy for site‐specific cancer treatment
Betrouni et al. Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning
ATE485836T1 (de) Mrt-geführte photodynamische therapie gegen krebs
Komolibus et al. Perspectives on interstitial photodynamic therapy for malignant tumors
Schaffer et al. Treatment of cervix carcinoma FIGO IIIb with Photofrin II as a radiosensitizer: a case report
Zuluaga et al. Selective photodetection and photodynamic therapy for prostate cancer through targeting of proteolytic activity
Betrouni et al. An image guided treatment platform for prostate cancer photodynamic therapy
JP2008522666A5 (de)
Spangler et al. Optimization of targeted two-photon PDT triads for the treatment of head and neck cancers
RU2204426C1 (ru) Способ фотодинамической диагностики и терапии больных первично-множественным раком кожи

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties